We will get there. The company has made the, necessary, change of path. They have put the drug into, possibly, a more receptive environment. Leronlimab's exposure, to the international medical community, grows every day. They have set up trials by a protocol that will let Leronlimab save lives and hit the primary and secondary endpoints with ease. We should have a better understanding of the explosive growth ahead, in either August or September (estimated, based on how fast enrollment goes and interim look). We just need patience and less FUD. I still believe the science will win.